Statements to nonpharmacologic treatment, assessing external validity is probably more difficult for trials assessing nonpharmacologic treatments (e.g., surgery, technical interventions, rehabilitation, psychotherapy, devices) than pharmacologic treatments (e.g., oral drugs)( , ). 18 19 The aim of this study was to evaluate and compare the reporting of external validity from RCTs assessing pharmacologic and nonpharmacologic treatments for hip and knee osteoarthritis (OA). We chose these conditions because they are highly prevalent and can result in disability and reduced quality of life. Further, international guidelines require the use of a combination of pharmacologic and nonpharmacologic treatments for optimal management of patients with these conditions( , ). 20 21
METHODS

Search strategy and selection of reports
We identified all English-language reports of RCTs indexed between January 2002 and December 2006 in PubMed using the search terms Osteoarthritis Hip OR Osteoarthritis Knee, with a limitation to RCTs, in MEDLINE via PubMed and to articles published in
English. A similar search strategy was used in a previous work on internal validity ( ). 22
Eligibility criteria and screening process
We collected the electronic records in an Endnote data file. One of us (AN) assessed each reports by screening the titles and abstracts to identify relevant studies. A second person (IB) checked for adequate selection of the abstracts. Articles were included if the study was identified as an RCT assessing pharmacologic or nonpharmacologic treatment for hip or knee OA in a parallel-group or cross-over design.
We excluded reports of cluster RCTs, nonrandomised trials, observational studies (cohort and case-control studies), extended follow-up trials (i.e., extended follow-up of patients included in an RCT beyond the last outcome assessment), nontherapeutic trials (metrological studies, epidemiological studies), pathophysiological studies, letters, an ancillary study of an RCT such as a subgroup analysis, cost-effectiveness evaluations, systematic reviews and/or meta-analyses. We also excluded reports of trials assessing the organization of the health care system or interventions provided to care providers. We excluded reports with these designs because we wanted to have a relatively homogeneous sample.
The selected abstracts were classified according to the category of treatment assessed: pharmacologic treatments, surgery or technical interventions (e.g., joint lavage), rehabilitation, or nonimplantable devices.
For each category of treatment, we used a computer-generated list to randomly select 30 articles and retrieved the full text articles.
Articles not fulfilling the inclusion criteria were replaced by a random selection of articles in the corresponding category. We chose a total of 120 articles for practical reasons, mainly to provide enough articles describing each category of treatment, and randomly selected articles to avoid selection bias.
Data collection
To assess external validity, as well as internal validity of the selected reports, we reviewed the literature and generated a standardized data extraction form (available upon request); we used items related to external validity proposed by the CONSORT Statement for RCTs (1 ) , the extension of the CONSORT Statement for nonpharmacologic trials( , ) and Rothwell et al.( ) Before data extraction, as a 18 19 5 calibration exercise, the standardized form was tested independently by two members of the team (AN, IB) on a separate set of 20 reports.
A meeting followed in which the ratings were reviewed and any disagreements were resolved by consensus. One reviewer (AN) independently completed all the data extraction. A random sample of 20 articles was reviewed for quality assurance.
The data extraction form covered the following data:
year of publication, journal, medical area of the study (i.e., hip OA, knee OA, hip and knee 1) Characteristics of the selected studies:
OA), type of treatment (i.e., pharmacologic treatment, surgical intervention, rehabilitation or education, nonimplantable device), type of control intervention (i.e., active intervention, placebo, usual care), funding sources (i.e., public, private, both, no funding, not reported or unclear), study design (i.e., parallel-group, cross-over) and sample size.
Internal validity of the selected reports was assessed with use of the following specific criteria recommended by the Cochrane collaboration and by most quality tools assessing results of pharmacologic and nonpharmacologic trials( , ): allocation sequence 10 12 generation; allocation concealment; blinding of patients, care providers and outcome assessors; and intent-to-treat (ITT) analysis.
2) External validity
The reporting of the following data related to external validity was evaluated: 3 15 : data on the method of recruitment (i.e., referral from a rheumatologist or general physician, self-selection of patients Recruitment through advertisement) and duration of recruitment.
: data on patients eligibility criteria as defined in a previous work ( ), inclusion criteria (i.e., criteria governing entry or Patients considered strongly justified if an individual or substitute decision-maker was unable to grant informed consent, the intervention or placebo would likely be harmful, the intervention would likely be ineffective, or the effect of the intervention would be difficult to interpret.
Data on the number of eligible patients, number of patients not meeting inclusion criteria and number of patients refusing to participate were collected. We also checked whether the article reported baseline characteristics of excluded patients, as well as essential data on baseline characteristics of randomized patients (i.e., age, sex, weight/body mass index, ethnicity, coexisting diseases or co-morbidities, duration of the disease, measure of function status, level of pain, description of radiographic evidence of damage, and use of nonsteroidal anti-inflammatory drugs).
: data on the number of centers/care providers, expertise of centers/care providers and details of the centers Centre and care provider (name, sources, organization, and expertise). The reporting of the number of patients recruited in each center or by each care provider was recorded.
(i.e., whether and how details on the interventions were reported): for pharmacologic treatments, the route of Intervention administration, dosage, duration, frequency of treatment, and patient compliance; for rehabilitation, the number, timing, duration and content of each session, mode of delivery, supervision or not, and patient compliance; for surgical interventions, the type of anaesthesia, pre-operative care, post-operative care, description of the technical procedure and surgeons compliance with the planned procedure; and ' for nonimplantable devices, the reporting of the manufacturer, description of the devices and patient compliance. information related to external validity reported in the abstract (i.e., country where the trial took Abstract and discussion sections: place, setting, number of centers, number of eligible patients, number of patients randomized, length of recruitment, length of follow-up, and data on care providers) and whether the external validity was discussed in the discussion section of the study as recommended by the CONSORT Statement ( ). 1 quantitative assessment of external validity reporting may offer complementary information. Global assessment of external validity:
Although it is difficult to specify which aspect of external validity is the most important, we decided to focus on 3 important components that are probably indispensable to assess the external validity of a trial: 1) the participants, 2) the description of the experimental treatment, and 3) the context of care (centres, setting, care providers expertise). For each component, we identified items that were considered ' essential to allow an adequate assessment of the external validity of a published trial. These items are described in the . The box quantitative assessment of external validity was evaluated by the percentage of the selected items that were adequately reported, for each component.
Statistical analysis
All data analyses were completed using SAS for Windows, Release 9.1 (SAS Institute, Cary, NC).
We used descriptive statistics for continuous variables: means, standard deviation (SD), median (lower quartile; upper quartile) and minimum and maximum values. Categorical variables are described with frequencies and percentages. The results were adjusted for the clustering effect by journals as recommended ( ). The reporting of data related to external validity according to category of treatment 24
was compared by a linear mixed-effects model, with the percentage of items with external validity as the dependent variable, fixed effects for treatment category, and journal as a random effect.
RESULTS
Articles selected
We identified 388 citations from our electronic search, of which 123 were excluded. Among the 265 included reports, we randomly chose 120 reports, 30 for each category of treatment. After obtaining and reviewing the full text, 11 articles were replaced. The flow of articles through the study is presented in appendix 1.
Characteristics of the selected studies 4 15 Characteristics of the included studies are reported in . The 120 articles were indexed in 53 journals. Among them, 13 (11 ) table 1 % were published in a general medical journal with a high impact factor and 107 (89 ) in a general medical journal with low impact factor % or in a special medical journal. Most trials, 118 (98 ), had a parallel-group design. Three-quarters of the reports assessed knee OA (n % = 90). The source of funding was described as public in 45 articles (38 ), completely or partially private in 25 (21 ) . A funding source was % % not reported in 50 reports (42 ) .
%
The median sample size (interquartile range) was 100 (60 216) and was twice as high for reports of pharmacologic trials as -nonpharmacologic trials.
The control group was described as receiving active treatment in 63 reports (52 ), a placebo intervention in 43 (36 ) and usual care % % in 14 (12 ) . Pharmacologic treatments and nonimplantable devices were mainly compared to placebo or active treatments, whereas % rehabilitation interventions were mainly compared to usual care or active treatments, and surgical procedures were compared to active treatment in most reports.
The generation of allocation sequences was adequate in 51 of the reports. The treatment allocation was adequately concealed in 41 % % of reports (n 49). Blinding was reported and was adequate in 43 of reports for patients, 32 for care providers and 59 for outcome
assessors. An ITT analysis was described in only one-third of the reports.
External validity
The results for assessing external validity are reported in and and . tables 2 3 figure 1
Recruitment (  )  table 2 The method of recruitment was described in about one-third of the reports; when described, this method relied on referral in 67 of (  )  table 2 Inclusion criteria were described in almost all reports (98 , n 118) and exclusion criteria in 88 (n 106). Exclusion criteria
focused on age in 53 of reports (n 64), medical co-morbidities in 66 (n 79), sex in 14 (n 17), medication in 48 (n 57),
socioeconomic status in 2 (n 3), and patients participating in another trial in 5 (n 6).
Twenty-three percent of reports poorly justified exclusion criteria. These rates did not differ by category of treatment.
A flow diagram of participants through the trial was given in 40 of reports (n 48). Data related to the number of eligible % = participants, number of participants not meeting inclusion criteria and those refusing participation were reported in less than half of the reports, but reporting was better for rehabilitation trials. When given, the mean rate of participants not meeting inclusion criteria and refusing to participate was 22.5 (30 ) and 19.2 (16 ), respectively.
% %
Baseline data of excluded participants were given in only one report. The baseline clinical characteristics of randomized participants were described in 91 of reports (n 109); characteristics concerned age and sex in more than 80 of reports, weight or body mass index
in 62 , and severity of disease (i.e., duration of the disease, pain, function, radiographic evidence of damage) in less than half. Patients
comorbidities were provided in only 12 of reports.
%
Interventions ( ) table 3
The treatments were described according to the CONSORT recommendations in all reports of pharmacologic trials and in most reports of rehabilitation trials but were missing in reports of devices and surgery trials. In the reports of medical device trials, a description of the device was given in 93 of reports (n 28), but the manufacturer was stated in only 30 (n 9). In the reports of surgical intervention % = % = trials, the technical procedure was given in all reports, but the type of anaesthesia was reported in only 13 (n 4), pre-operative care in 7 % = (n 2), and post-operative care in 50 (n 15). Control treatment was described in most reports (98 , n 117). Descriptions of
co-interventions were lacking in 23 of reports (n 28), mainly reports of pharmacologic trials.
% =
Centres and care providers (  )  table 2 The setting was described in 33 of reports (n 40) and the number of centres in 45 (n 54). The country where the trial took place sources, organization and expertise were never reported. The number of participants recruited in each centre was never reported. Details on care providers were given in 29 of reports (n 35).
Abstract and discussion sections
Information related to external validity was provided in the abstract of reports as follows: 4 of articles (n 5) described the country
where the trial took place, 15 (n 18) the setting, 12 (n 14) the number of centres, 2 (n 2) the number of eligible patients, 92 (n
110) the number of patients randomized, 5 (n 6) the length of recruitment, 82 (n 98) the length of follow-up, and 2 (n 2) data
on care providers. External validity was discussed in the discussion section of 11 articles (9 ). 
DISCUSSION
This study assessed the reporting of external validity in a sample of 120 RCTs assessing pharmacologic and nonpharmacologic treatments for hip or knee OA during a 5-year period. Our results highlight the lack of data related to external validity in published reports of RCTs. Methods for recruiting patients were described in one-third of the reports; 22.9 of the exclusion criteria were poorly justified; % important baseline data of patients were lacking; and setting, centers and care providers were described in one-third and less of articles.
Further, the reporting of external validity differed depending on the category of treatment. Reports of trials assessing rehabilitation provided more adequate data related to recruitment, participants, setting and centers, and intervention. On the contrary, reports of trials assessing surgical procedures lacked such data, even though the reporting of some items, such as the setting, the number of centers and center volume, is particularly important in this field. In reports of pharmacologic trials and trials assessing nonimplantable devices, the reporting was of varying quality. In reports of pharmacologic trials, the reporting of the method of recruitment and of data related to centers and care providers was poor, but the reporting of the intervention was good.
To our knowledge, this is the first study that systematically appraised the reporting of data related to external validity from trials assessing pharmacologic and nonpharmacologic treatments. Most recent efforts of researchers and editors to improve the reporting of results of RCTs, such as the CONSORT initiative, have mainly focused on internal validity ( , ). Nevertheless, external validity is also 1 9 essential and needs to be emphasized ( , ). The results of RCTs and systematic reviews cannot be relevant to all patients and all 25 26 settings. Consequently, reporting the results of RCTs should allow clinicians to judge to whom and in which context these results could reasonably be applied.
The setting, care providers and centers have obvious implications for external validity( , ). In fact, the applicability of results of 5 27 trials performed in secondary or tertiary settings applied to primary settings is often a concern ( ). Further, differences between health 5 care systems can affect the applicability of results, especially regarding organization of care or reimbursement for the cost of care( ). 5
These issues are crucial in trials assessing nonpharmacologic treatments such as surgery or technical interventions. In fact, hospital and care providers volume and outcome are related ( ). A surgical procedure might be found to be safe and effective in an RCT '
-33
performed in high-volume centres by high-volume care providers, but applying these results to low-volume centres might result in very different results ( , , ) . Surprisingly the reporting of data on care providers and centers was far less than optimal in our study, 27 34 35 especially for trials assessing surgical procedures.
The representativeness of patients included in a RCT is also a major issue for external validity. The inclusion and exclusion criteria are among the greatest challenges in achieving representativeness of participants. Highly selective eligibility criteria can considerably reduce the applicability of the trial results. Our results highlight the lack of reporting of exclusion criteria in 12 of the trial reports; 23 of The representativeness of the participants is also problematic because those agreeing to participate in RCTs often differ from those who do not participate. ( ). Consequently, the number of eligible nonrandomized patients, as well as the number of participants who 36 -39 were invited to participate but declined, is important to adequately appraise the external validity of a trial( ); however, these data were 22
reported in only one-third and one-quarter, respectively, of our reports, which is consistent with previous results ( ). 40
Reporting the baseline clinical characteristics of participants included in RCTs should allow clinicians and others to assess external validity by comparison with their patients. Although baseline characteristics were described in almost all of our reports, some important data were missing: weight or body mass index, while essential, was given in only 62 of the selected articles. The reporting of ethnicity, % comorbidities and severity and activity of the disease (pain, function, radiographic evidence of damage), which also predict response to and influence the generalisability of treatment was also inadequately reported ( ). 41 -44 External validity could also be affected if trials have treatment protocols that differ from usual clinical practice or have too stringent limitations on the use of cointerventions. Further, to be able to adequately apply the results of the trial in clinical practice, the treatments should be described in detail to allow for adequate reproducibility. Our results highlight the lack of descriptions of nontrial treatments in two-thirds of the reports of pharmacologic trials and that descriptions of all the components of nonpharmacologic trials were lacking, especially in reports of surgery ( ). 45
Finally, despite a specific item of the CONSORT Statement dedicated to external validity, very few articles considered this issue in the discussion section.
Our study has several limitations. First, we focused on the reporting of the trial, not its conduct. Consequently, these results highlight the lack of adequate reporting of external validity criteria and do not provide information on the applicability of the results of the trial.
Second, the results related to the rate of poorly justified exclusion criteria might be underestimated. In fact, some researchers have highlighted the inadequate reporting of eligibility criteria when comparing the published article with the protocol( ); among an average 46 of 31 eligibility criteria, only 63 were described in the main trial reports. Third, we focused on RCTs assessing hip and knee OA, and % these results should be confirmed in other medical areas. However, we chose this disease because it is frequent and involves a wide range of pharmacologic and nonpharmacologic treatments. Further, the authors had some expertise in rheumatology and orthopedics and could therefore adequately evaluate the context of the trials.
In conclusion, this study highlights the lack of consideration of external validity in published reports of RCTs. Much attention is paid to the internal validity of clinical trials; however, even results of well-designed clinical trials are of limited use to clinicians if they have poor external validity and are not applicable to the patients for whom the intervention is designed. Recently the CONSORT group developed an extension of the CONSORT Statements for pragmatic trials. This extension increases the focus on data related to external validity. This initiative should help improve the consideration of external validity.
Box
Components of external validity evaluated in selected reports of trials of pharmacologic and nonpharmacologic treatments for hip and knee osteoarthritis 7 15 Description of participants Percentage of the following baseline data reported Table 2 Number ( ) of selected reports of trials of pharmaceutical and nonpharmaceutical treatments for hip and knee osteoarthritis that described items related to external validity 
